Adults over 60 years old USA soon they could get the single dose of the vaccine against syncytal virusresponsible for diseases such as bronchiolitis and pneumonia.
In a statement, the US Food and Drug Administration (FDA) approved the use of the Arexvy vaccine from British pharma giant GSK. According to Peter Marks, the president of the FDA, “It’s a major public health achievement in preventing a disease that can be deadly.”
Today we approved the first respiratory syncytial virus (RSV) vaccine, approved for use in the US, for the prevention of RSV-induced lower respiratory tract disease in individuals 60 years and older.
More information: https://t.co/V6ChIMKcYt pic.twitter.com/DgmkzjIR42
—US FDA (@US_FDA) May 3, 2023
According to the FDA study, the vaccine would have 83% effective against symptomatic disease and 94% against severe disease. In the clinical trial, scientists and researchers administered doses of the vaccine and placebo to 2,500 participants, with favorable results.
The European Medicines Agency (EMA) also gave the green light to this drug as a preventative.
In the United States alone, it causes syncytial virus the death of between 6,000 and 10,000 people over the age of 65 years by causing a respiratory infection. Young children are also affected by this virus, which mainly attacks in winter.
Source: Eluniverso
Mabel is a talented author and journalist with a passion for all things technology. As an experienced writer for the 247 News Agency, she has established a reputation for her in-depth reporting and expert analysis on the latest developments in the tech industry.
